Advances in Alzheimer's disease's pharmacological treatment

被引：28

作者：

Conti Filho, Carlos Elias ^{[1
]}

Loss, Lairane Bridi ^{[1
]}

Marcolongo-Pereira, Clairton ^{[1
]}

Rossoni Junior, Joamyr Victor ^{[1
]}

Barcelos, Rafael Mazioli ^{[1
]}

Chiarelli-Neto, Orlando ^{[1
]}

Silva, Bruno Spalenza da ^{[1
]}

Passamani Ambrosio, Roberta ^{[1
]}

Castro, Fernanda Cristina de Abreu Quintela ^{[1
]}

Teixeira, Sarah Fernandes ^{[1
]}

Mezzomo, Nathana Jamille ^{[1
]}

机构：

[1] Univ Ctr Espirito Santo, Fac Med, Colatina, Brazil

来源：

FRONTIERS IN PHARMACOLOGY | 2023年 / 14卷

关键词：

Alzheimer's disease; molecular target; drug development; pharmacological treatment; new drugs; GLUTAMINYL CYCLASE INHIBITORS; AMYLOID-BETA; DOUBLE-BLIND; ACETYLCHOLINESTERASE INHIBITORS; RANDOMIZED-TRIAL; PHASE-II; MILD; SAFETY; TAU; EFFICACY;

D O I：

10.3389/fphar.2023.1101452

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Alzheimer's disease (AD) is the most common type of dementia in the elderly. Several hypotheses emerged from AD pathophysiological mechanisms. However, no neuronal protective or regenerative drug is available nowadays. Researchers still work in drug development and are finding new molecular targets to treat AD. Therefore, this study aimed to summarize main advances in AD pharmacological therapy. Clinical trials registered in the National Library of Medicine database were selected and analyzed accordingly to molecular targets, therapeutic effects, and safety profile. The most common outcome was the lack of efficacy. Only seven trials concluded that tested drugs were safe and induced any kind of therapeutic improvement. Three works showed therapeutic effects followed by toxicity. In addition to aducanumab recent FDA approval, antibodies against amyloid-beta (A beta) showed no noteworthy results. 5-HT6 antagonists, tau inhibitors and nicotinic agonists' data were discouraging. However, anti-A beta vaccine, BACE inhibitor and anti-neuroinflammation drugs showed promising results.

引用

页数：9

共 50 条

[1] Pharmacological treatment of Alzheimer's disease
Bianchetti, A
Ranieri, P
Margiotta, A
Trabucchi, M
[J]. AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2006, 18 (02) : 158 - 162
[2] Pharmacological treatment of Alzheimer’s Disease
Angelo Bianchetti
Piera Ranieri
Alessandro Margiotta
Marco Trabucchi
[J]. Aging Clinical and Experimental Research, 2006, 18 : 158 - 162
[3] Advances in the treatment of Alzheimer's disease
Sloane, PD
[J]. AMERICAN FAMILY PHYSICIAN, 1998, 58 (07) : 1577 - 1586
[4] Advances in the treatment of Alzheimer's disease
Schneider, LS
[J]. AGING-CLINICAL AND EXPERIMENTAL RESEARCH, 1998, 10 (02): : 156 - 157
[5] Advances in Alzheimer's disease treatment
Nourhashemi, F.
[J]. REVUE DE MEDECINE INTERNE, 2006, 27 (08): : 585 - 587
[6] Pharmacological and non pharmacological treatment of Alzheimer's disease
Awada, A.
[J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2019, 405
[7] Pharmacological and non pharmacological treatment of Alzheimer's disease
Abdel-Naseer, M.
[J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2019, 405
[8] Alzheimer's disease: Pharmacological treatment and management
Rivas-Vazquez, RA
Carrazana, EJ
Rey, GJ
Blais, MA
Racher, DA
[J]. CLINICAL NEUROPSYCHOLOGIST, 2000, 14 (01) : 93 - 109
[9] Update on the Pharmacological Treatment of Alzheimer's Disease
Massoud, Fadi
Gauthier, Serge
[J]. CURRENT NEUROPHARMACOLOGY, 2010, 8 (01) : 69 - 80
[10] Non pharmacological treatment in Alzheimer's disease
Bianchetti, A
Zanetti, O
Trabucchi, M
[J]. FUNCTIONAL NEUROLOGY, 1997, 12 (3-4) : 215 - 217

← 1 2 3 4 5 →